Valeant Pharmaceuticals
Ocular Therapeutix looks to raise $80M in IPO | Medtech Wall Street news for the week of July 14, 2014
Covidien shareholder files class action lawsuit blocking company’s merger with Medtronic | The week in medtech M&A
Allergan renews fight against hostile Valeant takeover
Valeant, hedge fund look to oust Allergan board members | MassDevice.com On Call
MASSDEVICE ON CALL — Valeant Pharmaceuticals and its hedge fund partner, Pershing Square Capital Management, asked Allergan (NYSE:AGN) shareholders today to oust Allergan’s board and replace it with a slate of its own directors.
Allergan reveals FDA win, lobbies to keep Valeant out
Embattled device maker Allergan (NYSE:AGN) hopes it can keep unwelcome buyer Valeant Pharmaceuticals from getting its hands on the company’s advancing R&D pipeline.